MDMi Cell Model for Neurodegenerative Disease Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack an efficient in vitro model for human microglia, limiting the study of neurodegenerative diseases and the development of targeted therapeutic agents, as primary human microglia are scarce and rapidly lose their identity when cultured outside the brain environment.
Innovation Solution
The use of human monocyte-derived microglia-like (MDMi) cells, which can be cultured and differentiated to resemble microglial subtypes, allowing for the assessment of clinical interventions, stratification of patient populations, and identification of neurodegenerative disease biomarkers and therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If primary human microglia are used as a model, then the model accurately represents microglial function, but the model is difficult to obtain and maintain due to limited availability and rapid loss of identity in culture
Solution Approach 1:
The patent creates a copy of primary human microglia by differentiating monocytes in vitro into microglia-like cells (MDMi cells). These induced microglia replicate the key functional characteristics of primary microglia including phagocytic activity, synaptic pruning capability, and response to neuronal cues, while being obtainable from easily accessible peripheral blood monocytes rather than requiring invasive brain tissue extraction.
Solution Approach 2:
The patent uses an intermediary differentiation protocol involving specific cytokine treatment (IL-34, IL-6, TNF-alpha) to convert readily available monocytes into microglia-like cells. This intermediary process allows the transformation of easily obtainable peripheral cells into functionally relevant microglial models without requiring direct access to brain-resident microglia.
2Ease of manufacture
If transformed microglial-like cell lines are used, then the model is easily propagated and maintained, but the model is highly proliferative and therefore not suitable for studying non-proliferating differentiated microglia
Solution Approach 1:
The patent changes the proliferation parameter of microglial models by inducing monocytes to differentiate into microglia-like cells that exhibit reduced proliferative capacity compared to transformed cell lines. The MDMi cells maintain a more stable, non-proliferating state that better reflects physiological microglia, while still being derivable from easily obtainable monocyte precursors through controlled differentiation protocols.
Data Source
AI summary
Provided herein are methods and compositions related to the use of human monocyte-derived microglia-like (MDMi) cells. In some embodiments, the methods and compositions provided herein relate to the use of MDMi cells to assess the effect of a clinical intervention on a human subject (e.g., a subject with a neurodegenerative disorder). In some embodiments, the methods and compositions provided herein relate to the use of MDMi cells to stratify human subjects into subgroup populations (e.g., populations that are likely to respond to a clinical intervention or are unlikely to respond to a clinical intervention). In some embodiments, the methods and compositions provided herein relate to the use of MDMi cells to identify candidate neurodegenerative disease biomarkers. In certain embodiments, the methods and compositions provided herein relate to the use of MDMi cells to screen potential therapeutic agents to identify candidate agents for the treatment of a neurodegenerative disease.